Medical application of berberine

A technology of berberine and medicine, which is applied in the field of medical application of berberine, can solve the problems such as weak effect of ischemic cardiomyopathy, achieve the effect of improving right ventricular function, reducing mean pulmonary artery pressure, and preventing and treating heart failure

Active Publication Date: 2017-06-13
陈绍良
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently used β-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors, and angiotensin receptor antagonists all have a variety of side effects, and the effect of preventing ischemic cardiomyopathy is weak

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of berberine
  • Medical application of berberine
  • Medical application of berberine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Prevention and treatment of pulmonary hypertension and right heart failure

[0026] Cell experiments:

[0027] Using normal animal pulmonary artery smooth muscle cells, Grk2 and LKB1, which are the most common high expressions in right heart failure, were significantly increased after being stimulated by norepinephrine for different times, while they were significantly decreased in the CTL group after adding berberine for 30 minutes at the same time. The results showed that berberine had a prominent effect on resisting norepinephrine-stimulated pulmonary artery smooth muscle cells ( figure 1 )

[0028] Animal experiment:

[0029] Select 20 Beagle dogs, measure pulmonary artery hemodynamics, and randomly divide them into berberine (fed by gavage, 0.1g / d, 14 days in total) and control group (gavage with berberine sugar-coated layer, without berberine) berberine for a total of 14 days). On the 14th day, dehydromonocrotaline (60 mg / kg) was injected into the right atrium...

Embodiment 2

[0033]Prevention and treatment of in-stent restenosis and in-stent thrombosis

[0034] 100 patients after implantation of drug-eluting stents were randomly divided into two groups: the control group (without taking berberine) and the berberine group (adding berberine 0.3 / d, 6 months in total), coronary angiography was repeated at 12 months after operation. Results: The proportion of in-stent restenosis in the control group was 14% (N=7), and only 2 cases in the berberine group had restenosis (4%, p=0.035), and the degree of stenosis was significantly lower than that in the control group (58±4% versus 76.3±9%, p=0.029). In the control group, 7 patients with restenosis were orally administered berberine (0.3 / d, for a total of 6 months), and they were followed up for 9 months. As a result, the degree of stenosis in 6 patients was significantly reduced ( Figure 5 ).

Embodiment 3

[0036] Prevention and treatment of myocardial infarction

[0037] Thirty myocardial infarction model animals were randomly divided into control group and berberine feeding group. The results showed that berberine (0.3g, 3 times a day, after 3 months) myocardial cell apoptosis was significantly reduced ( Image 6 Left panel), electron microscopy confirmed the reduction of apoptotic bodies ( Image 6 Right panels A-C). The arrangement of cardiomyocytes in the berberine treatment group was relatively complete.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention discloses medical application of berberine. The berberine has prominent functions of resisting noradrenaline and stimulating pulmonary arterial smooth muscle cells and is capable of effectively improving the function of a right ventricular, and meanwhile, the berberine is capable of remarkably reducing mean pulmonary arterial pressure; the functions of preventing in-stent restenosis and stent thrombosis are obtained; the berberine has a unique function of preventing and treating myocardial infarction; the berberine is capable of effectively preventing and treating ischemic cardiomyopathy and cardiac failure caused thereby.

Description

technical field [0001] The invention belongs to the technical field of chemical medicines, and in particular relates to the medical application of berberine. Background technique [0002] Pulmonary hypertension: Pulmonary hypertension is characterized by a progressive increase in pulmonary artery pressure (average pulmonary artery pressure <25 mmHg at normal rest) and pulmonary vascular resistance (<2.5 WU at normal rest), rapidly leading to right heart failure and premature death. The pulmonary arteries are venous vessels in which the blood flowing carries a low oxygen carrying capacity. Pulmonary arterial pathological remodeling occurs in pulmonary hypertension, manifested as extreme hyperplasia of smooth muscle in the middle layer of small distal pulmonary arteries, abnormal and impaired endothelial cell function, in situ thrombosis, and plexiform changes, resulting in a significant increase in pulmonary artery pressure and pulmonary vascular resistance. Causes e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P9/12A61P11/00A61P9/10A61P9/04
CPCA61K31/4375A61P11/00A61P9/04A61P9/10A61P9/12
Inventor 陈绍良
Owner 陈绍良
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap